225 related articles for article (PubMed ID: 15550269)
21. Efficacy of herpes virus helicase-primase inhibitor, ASP2151, for treating herpes simplex keratitis in mouse model.
Sasaki S; Miyazaki D; Haruki T; Yamamoto Y; Kandori M; Yakura K; Suzuki H; Inoue Y
Br J Ophthalmol; 2013 Apr; 97(4):498-503. PubMed ID: 23361434
[TBL] [Abstract][Full Text] [Related]
22. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo.
Liuzzi M; Déziel R; Moss N; Beaulieu P; Bonneau AM; Bousquet C; Chafouleas JG; Garneau M; Jaramillo J; Krogsrud RL
Nature; 1994 Dec; 372(6507):695-8. PubMed ID: 7990963
[TBL] [Abstract][Full Text] [Related]
23. Pathogenicity and response to topical antiviral therapy in a murine model of acyclovir-sensitive and acyclovir-resistant herpes simplex viruses isolated from the same patient.
Lebel A; Boivin G
J Clin Virol; 2006 Sep; 37(1):34-7. PubMed ID: 16781887
[TBL] [Abstract][Full Text] [Related]
24. Genotypic and phenotypic characterization of acyclovir-resistant herpes simplex viruses isolated from haematopoietic stem cell transplant recipients.
Stránská R; van Loon AM; Polman M; Beersma MF; Bredius RG; Lankester AC; Meijer E; Schuurman R
Antivir Ther; 2004 Aug; 9(4):565-75. PubMed ID: 15456088
[TBL] [Abstract][Full Text] [Related]
25. Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model.
Uhlig N; Donner AK; Gege C; Lange F; Kleymann G; Grunwald T
Antiviral Res; 2021 Nov; 195():105190. PubMed ID: 34666109
[TBL] [Abstract][Full Text] [Related]
26. New antiviral drugs that target herpesvirus helicase primase enzymes.
Kleymann G
Herpes; 2003 Aug; 10(2):46-52. PubMed ID: 14577954
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of virus-encoded thymidine kinase suppresses herpes simplex virus replication in vitro and in vivo.
Watkins AM; Dunford PJ; Moffatt AM; Wong-Kai-In P; Holland MJ; Pole DS; Thomas GM; Martin J; Roberts NA; Mulqueen MJ
Antivir Chem Chemother; 1998 Jan; 9(1):9-18. PubMed ID: 9875372
[TBL] [Abstract][Full Text] [Related]
28. Acyclovir susceptibility and genetic characteristics of sequential herpes simplex virus type 1 corneal isolates from patients with recurrent herpetic keratitis.
Duan R; de Vries RD; van Dun JM; van Loenen FB; Osterhaus AD; Remeijer L; Verjans GM
J Infect Dis; 2009 Nov; 200(9):1402-14. PubMed ID: 19795980
[TBL] [Abstract][Full Text] [Related]
29. UL52 primase interactions in the herpes simplex virus 1 helicase-primase are affected by antiviral compounds and mutations causing drug resistance.
Muylaert I; Zhao Z; Elias P
J Biol Chem; 2014 Nov; 289(47):32583-92. PubMed ID: 25278021
[TBL] [Abstract][Full Text] [Related]
30. Herpes simplex virus helicase-primase inhibitors: recent findings from the study of drug resistance mutations.
Biswas S; Field HJ
Antivir Chem Chemother; 2008; 19(1):1-6. PubMed ID: 18610552
[TBL] [Abstract][Full Text] [Related]
31. Characterization and susceptibility to antiviral agents of herpes simplex virus type 1 containing a unique thymidine kinase gene with an amber codon between the first and the second initiation codons.
Saijo M; Suzutani T; Mizuta K; Kurane I; Morikawa S
Arch Virol; 2008; 153(2):303-14. PubMed ID: 18066636
[TBL] [Abstract][Full Text] [Related]
32. Deletion mutants of the herpes simplex virus type 1 UL8 protein: effect on DNA synthesis and ability to interact with and influence the intracellular localization of the UL5 and UL52 proteins.
Barnard EC; Brown G; Stow ND
Virology; 1997 Oct; 237(1):97-106. PubMed ID: 9344911
[TBL] [Abstract][Full Text] [Related]
33. A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure.
Biswas S; Miguel RN; Sukla S; Field HJ
J Gen Virol; 2009 Aug; 90(Pt 8):1937-1942. PubMed ID: 19403757
[TBL] [Abstract][Full Text] [Related]
34. Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor.
Yajima M; Yamada H; Takemoto M; Daikoku T; Yoshida Y; Long T; Okuda T; Shiraki K
Antiviral Res; 2017 Mar; 139():95-101. PubMed ID: 28027917
[TBL] [Abstract][Full Text] [Related]
35. Genotypic characterization of the DNA polymerase and sensitivity to antiviral compounds of foscarnet-resistant herpes simplex virus type 1 (HSV-1) derived from a foscarnet-sensitive HSV-1 strain.
Saijo M; Suzutani T; Morikawa S; Kurane I
Antimicrob Agents Chemother; 2005 Feb; 49(2):606-11. PubMed ID: 15673740
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of ASP2151, a helicase-primase inhibitor, against thymidine kinase-deficient herpes simplex virus type 2 infection in vitro and in vivo.
Himaki T; Masui Y; Chono K; Daikoku T; Takemoto M; Haixia B; Okuda T; Suzuki H; Shiraki K
Antiviral Res; 2012 Feb; 93(2):301-304. PubMed ID: 22155691
[TBL] [Abstract][Full Text] [Related]
37. Biological characterization of eugeniin as an anti-herpes simplex virus type 1 compound in vitro and in vivo.
Kurokawa M; Hozumi T; Tsurita M; Kadota S; Namba T; Shiraki K
J Pharmacol Exp Ther; 2001 Apr; 297(1):372-9. PubMed ID: 11259565
[TBL] [Abstract][Full Text] [Related]
38. UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients.
Labrunie T; Ducastelle S; Domenech C; Ader F; Morfin F; Frobert E
Antiviral Res; 2019 Aug; 168():114-120. PubMed ID: 31152759
[TBL] [Abstract][Full Text] [Related]
39. The three-component helicase/primase complex of herpes simplex virus-1.
Bermek O; Williams RS
Open Biol; 2021 Jun; 11(6):210011. PubMed ID: 34102080
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of anise oil, dwarf-pine oil and chamomile oil against thymidine-kinase-positive and thymidine-kinase-negative herpesviruses.
Koch C; Reichling J; Kehm R; Sharaf MM; Zentgraf H; Schneele J; Schnitzler P
J Pharm Pharmacol; 2008 Nov; 60(11):1545-50. PubMed ID: 18957177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
